… A 2-part, phase 3 randomized clinical trial among asymptomatic household contacts of …
antibody), would prevent infection and/or COVID-19 in this high-risk setting. In Part A of the trial, …

… In the first stage, we excluded clinical trials not apparently comparing the combination of
aspirin and heparin and aspirin alone (n = 9), irrelevant trials (n = 15), non-RCTs (n = 2) and five …

… The two-antibody combination reduces the risk of … We conducted a phase 3, randomized
controlled trial in … 1200 mg (600 mg of each monoclonal antibody) may prevent infection and/or …

… Prevention Trial Team. Effect of subcutaneous casirivimab and imdevimab antibody combination
vs … COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial.  …

… Combining these 2 neutralizing monoclonal antibodies in clinical use may enhance viral load
… Third, only 1 combination dose was chosen for this study. Because the antiviral activity of …

… 1 and (3 + 3 mg kg −1 , 10 + 10 mg kg −1 or 30 + 30 mg kg −1 ) in group 2 were randomized
at a ratio of three antibody recipients to one placebo recipient, respectively (total of nine …

… These new options for patients with advanced or metastatic colorectal cancer raised the
question of which was the optimal biologic monoclonal antibody-chemotherapy combination. …

… Following stabilization, they were randomized to 1 of 7 … monotherapy or in combination
with MTX, or MTX plus placebo. … antibodies developed against this murine antibody (30). …

… However, to the best of our knowledge no trials to test the efficacy and … , randomized,
placebo-controlled, double-blind clinical trial to evaluate the efficacy and safety of IVIG combined …

Background Preclinical studies suggest that interleukin-9 may be a central mediator in the
development and maintenance of airway inflammation in asthma. The aim of this study was …